The trajectory of trust shapes revenue, making trust a financial imperative

Trust isn’t soft; it’s a financial lever. The chart shows that Edelman’s global trust index for pharma dropped from 54 in 2002 to 37 in 2012, then gradually recovered to around 52 by 2025, edging back into the neutral zone. However, Gallup’s U.S. sentiment data tells a different story: positive views of pharma fell from roughly 32% to just 20% in 2024, ranking it the least-favored of 25 industries. This divergence highlights that institutional confidence may be stabilizing, but public trust and likability continue to erode, even amid major scientific milestones such as the COVID-19 vaccine rollout (2020–21) and the rise of mRNA-based therapies. Together, these trends reveal pharma’s core challenge: a widening credibility gap that undermines its ability to translate scientific progress into public trust and financial performance. Here are the key takeaways of our findings:

• Trust deficit at historic lows: Consumer trust in pharma is at a historic low despite a temporary bump during the pandemic, when companies such as Pfizer and Moderna gained credibility for delivering vaccines quickly.
• There are financial implications of low trust: Even if non-tangible, trust can have its own ways to affect the financial imperative.
  • Therapy adoption slows when patients and clinicians hesitate to embrace new drugs.
  • Policy risk rises as governments become more willing to impose pricing controls and regulatory oversight (e.g., IRA).
  • Patient engagement strategies stall, making it harder to scale precision medicine and digital health.
  • Brand equity erodes, weakening pricing power and launch velocity.
• Compounding revenue challenges: The trust deficit magnifies the revenue cliff from the Inflation Reduction Act (IRA) and the end of blockbusters. Instead of just an earnings headwind, distrust creates systemic friction across adoption, pricing, and engagement models.
• Pharma is in a double bind: Revenues are collapsing structurally, and trust is too low to support new growth engines such as precision medicine and patient-centric engagement. We had talked about the industry’s revenue challenge in our previous writeup.

The Bottom Line: Pharmas must make “rebuilding trust” a core KPI to turn scientific innovation into sustainable business outcomes.